secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-065511
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase reports 2024 net loss $27.5M; cash $97.5M; PAH trial progress, new leadership
--------------------------------------------------------------------------------

- Net loss $27.5M ($1.16 per share) vs $19.1M ($3.16 per share) in 2023; R&D $17.2M, SG&A $11.4M.
- Cash, cash equivalents and marketable securities $97.5M as of December 31, 2024.
- Closed $110M private placement in October 2024 (up to $275M if warrants exercised).
- Appointed Mark Iwicki CEO, Chris Cabell President & Head of R&D, John Adams CSO; added new board members.
- Received Study May Proceed letter for Phase 2b trial of IkT-001 in PAH in September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525065511/0001193125-25-065511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525065511/d943685d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-065511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer